trending Market Intelligence /marketintelligence/en/news-insights/trending/QXCCXZIhyL-25sG1hXTzNw2 content esgSubNav
In This List

AgeX Therapeutics starts operations with $10M in equity financing

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

Blog

Commercial Banking Newsletter June Edition - 2022


AgeX Therapeutics starts operations with $10M in equity financing

BioTime Inc. subsidiary AgeX Therapeutics Inc. raised $10 million through an equity financing to fund its operations.

BioTime, IBS Capital LLC, KIZOO Technology Capital GmbH and certain individual investors participated in the financing.

BioTime continues to own about 87% of AgeX's shares. AgeX was created in April to consolidate certain subsidiaries and programs in the field of interventional gerontology, the treatment of age-related diseases.

BioTime's co-CEO, Michael West, will serve as AgeX's CEO.